Business Wire

Fashion Concept GmbH: Jeremy Meeks to conquer fashion world

Share

We are experiencing a time of social and technological revolution. Fashion Concept GmbH is not just a pioneer, it has also been able to sign a deal with one of the icons of the fashion industry, former "hot felon" Jeremy Meeks. Fashion Concept GmbH focuses on the international trade in textiles. By using sustainable materials and promoting investment in new technologies, the company aims to ensure the long-term availability of environmentally-friendly fashion.

The company's goal is to set new standards for sustainability. To reinforce this goal, Fashion Concept has just signed a $15 million deal with Jeremy Meeks to develop his own brand. For Meeks, who has been a regular presence on the catwalk for various fashion designers, this collaboration means a higher profile and a wider audience, because not only will he be a top model, but he will also be marketing his own fashion label.

It is not just this mega deal that is a milestone in Jeremy's career; his private life is also on the upswing. He was recently photographed with a well-known actress. But things are not just on the upswing for Jeremy: Fashion Concept GmbH, with its focus on uniquely innovative and sustainable technologies, is making a bold move with this deal as it seeks to drive forward change in the fashion industry. Fashion Concept aims to expand the growth in fashion and lifestyle brands. Higher revenues are being generated each year on Germany's fashion market, in retail and, in particular, through online business; private investors, too, will soon have the opportunity to benefit from this growth. The profit margins of often up to 30% will be of particular interest for investors.

This is precisely the market segment where Fashion Concept is active. In international trade, the company has seen a growth of almost 300% in its sales over the last two years alone. The company is already making profits in purchasing, since it can access its own production facilities in Turkey. In addition, merchandise such as textiles and accessories from many top manufacturers are being produced and purchased at very favourable conditions. The opportunity to purchase at high volumes allows savings of up to 90% to be achieved.

The company plans to purchase further top textile brands in 2020. This will not only expand its product offerings significantly, it will also have a direct impact on prices.

The group works with numerous distributors, allowing it to be able to choose the most efficient marketing channel for its products at all times. In this way, it can maximise the revenue from the quick sale of its merchandise.

The company does not rely on bank loans, but instead uses subordinated loans, bonds, profit participation rights, and silent partnerships for individuals who can directly benefit from the company's growth with a fixed return, currently at three to five percent.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Name:Oguzhan Dertli
Tel: 00905392010251
Email:ahmet@fashion-concept.com

Fashion Invest AG
De-Saint-Exupéry-Straße 10
60549 Frankfurt am Main
Tel.: +4969348713577

Email: press@fashion-invest.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye